Page last updated: 2024-11-05

zalcitabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Zalcitabine, also known as ddC, is a nucleoside analog antiretroviral drug used in the treatment of HIV infection. It is a potent inhibitor of HIV reverse transcriptase, an enzyme essential for the replication of the virus. Zalcitabine is synthesized through a complex multi-step process involving the modification of a sugar molecule. It works by interrupting the viral DNA synthesis, preventing the virus from replicating and spreading. Zalcitabine was the first approved antiretroviral for the treatment of AIDS, and it has been studied extensively for its potential benefits in combating HIV infection. Its effectiveness in slowing the progression of HIV disease has been demonstrated in several clinical trials. However, zalcitabine can cause significant side effects, including peripheral neuropathy, pancreatitis, and lactic acidosis. Due to the development of newer, more effective and safer antiretroviral drugs, zalcitabine is now rarely used as monotherapy, but it is still used in combination therapy with other antiretrovirals for certain patients. It is being studied in combination with other agents for the treatment of various cancers and other viral infections.'

Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24066
CHEMBL ID853
CHEBI ID10101
SCHEMBL ID3598
MeSH IDM0024532

Synonyms (171)

Synonym
SRI-7707-13
SRI-7707-14
DDC ,
nsc-606170
MLS000069636
smr000058253
4-amino-1-[(2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1h)-one
zalcitibine
EU-0100360
pc-sod & ddc
lecithinized superoxide dismutase & .beta.-d-2',3'-dideoxycytidine
2',3'-dideoxycytidine, >=98% (hplc)
hsdb 7156
cytidine, 2',3'-dideoxy-
nsc 606170
hivid
ro-24-2027/000
ccris 692
TIMTEC1_004969
brn 0654956
BPBIO1_001378
LOPAC0_000360
cas-7481-89-2
NCGC00179242-01
ds-4152 & ddc
ddc & np (from phca or hsa)
BSPBIO_001253
PRESTWICK3_001037
PRESTWICK2_001037
cytidine, 2',3'-dideoxy- & interferon.alpha.
2',3'-dideoxycytidine & interferon.alpha.
ddc & scd4
ddc & gm-csf
ro 24-2027/000
hivid(tm)
cytidine, 2',3'-dideoxy- & colony-stimulating factor
.beta.-d-2',3'-dideoxycytidine
.beta.-d-2',3'-dideoxycytidine & granulocyte-macrophage colony-stimulating factor
ddcyd
dideoxycytidine
ddc & interferon.alpha.
ddc & ifn.alpha.
4-amino-1-[(2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
.beta.-d-ddc
2',3'-dideoxycytidine & scd4(soluble recombinant protein)
NCGC00090705-01
UPCMLD-DP115:001
MLS001424210
SRI-7707 ,
7481-89-2
zalcitabine
2',3'-dideoxycytidine ,
C07207
MLS000759540
DB00943
UPCMLD-DP115
zalcitabine (jan/usp/inn)
D00412
hivid (tn)
NCGC00090705-05
NCGC00090705-07
SPBIO_003104
PRESTWICK1_001037
PRESTWICK0_001037
3'-azido-3'-deoxythymidine/2',3'-dideoxycytidine
interferon ad + ddc
NCGC00090705-02
NCGC00090705-03
NCGC00090705-06
MLS001055363
HMS2051H18
AC-824
HMS1548B19
D 5782 ,
HMS2090C12
D3581
NCGC00090705-10
bdbm50145605
ro-24-2027000
zalcitabine (dideoxycytidine,ddc)
ddc (ddc)
ro-242027000
CHEMBL853 ,
1-(2,3-dideoxy-beta-d-ribofuranosyl)cytosine
4-amino-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
BMSE000712
2,3-dideoxycytidine
CHEBI:10101 ,
HMS1571O15
A838234
NCGC00090705-11
NCGC00090705-08
NCGC00090705-13
NCGC00090705-09
HMS3261G21
HMS2098O15
tox21_303169
dtxsid0023747 ,
dtxcid703747
NCGC00257202-01
tox21_113491
tox21_201655
NCGC00259204-01
pharmakon1600-01502360
nsc-759655
nsc759655
HMS2236N08
CCG-101050
unii-6l3xt8cb3i
6l3xt8cb3i ,
zalcitabine [usan:usp:inn:ban]
5-25-14-00313 (beilstein handbook reference)
HY-17392
CS-1110
LP00360
S1719
AKOS015894505
AKOS015854844
gtpl4828
ro-242027000/ro-24-2027-000
4-amino-1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
dideoxycytidine (ddc)
zalcitabine [usp-rs]
zalcitabine [iarc]
zalcitabine [mart.]
zalcitabine [inn]
zalcitabine [hsdb]
zalcitabine [orange book]
zalcitabine (dideoxycytidine,ddc) [vandf]
zalcitabine [mi]
zalcitabine [usp impurity]
zalcitabine [who-dd]
zalcitabine [vandf]
zalcitabine [usan]
zalcitabine [jan]
NC00300
SCHEMBL3598
tox21_113491_1
NCGC00090705-15
zalcitabine, 2'3'-dideoxycytidine
KS-1130 ,
NCGC00261045-01
tox21_500360
J-700276
2', 3'-dideoxycytidine
4-amino-1-((2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one
MLS006011951
Q-201941
SRI-7707_17
SRI-7707_15
sr-01000736919
SR-01000736919-5
2',3'-dideoxycytidine, >=99.0% (hplc)
zalcitabine, united states pharmacopeia (usp) reference standard
EN300-120633
4-amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidin-2-one
SR-01000075822-1
sr-01000075822
HMS3715O15
Z1550648753
SW197364-4
ddc;dideoxycytidine;2',3'-dideoxycytidine
BD164564
BCP13878
Q2344582
SDCCGSBI-0050348.P002
NCGC00090705-25
C76390
NCGC00090705-24
zalcitabine- bio-x
BP-58631

Research Excerpts

Overview

Zalcitabine is an antiretroviral nucleoside analogue. It exhibits long-term toxicity to hepatocytes by interfering with the replication of mitochondrial DNA (mtDNA)

ExcerptReferenceRelevance
"Zalcitabine is an antiretroviral nucleoside analogue that exhibits long-term toxicity to hepatocytes by interfering with the replication of mitochondrial DNA (mtDNA). "( Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
Kirschner, J; Lebrecht, D; Setzer, B; Vargas-Infante, YA; Walker, UA, 2007
)
2.06
"Zalcitabine is a potent nucleoside analogue inhibitor of reverse transcriptase used in the treatment of HIV infection."( Zalcitabine. Clinical pharmacokinetics and efficacy.
Devineni, D; Gallo, JM, 1995
)
2.46
"Zalcitabine is a dideoxynucleoside antiretroviral agent that is phosphorylated to the active metabolite 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) within both uninfected and HIV-infected cells. "( Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins, JC; Faulds, D; Peters, DH, 1997
)
3.18
"Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. "( Finding a role for zalcitabine in the HAART era.
Gazzard, BG; Moyle, GJ, 1998
)
2.07

Actions

ExcerptReferenceRelevance
"Zalcitabine can cause peripheral neuropathy (in 17 to 31% of patients), which is dose-related and is completely reversible when the drug is discontinued."( Zalcitabine. Clinical pharmacokinetics and efficacy.
Devineni, D; Gallo, JM, 1995
)
2.46

Treatment

ExcerptReferenceRelevance
"Both zalcitabine groups were treated with or without Mitocnol (0.34 g/kg/d), a dietary supplement with high bioavailability of uridine."( Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
Kirschner, J; Lebrecht, D; Setzer, B; Vargas-Infante, YA; Walker, UA, 2007
)
1.07

Toxicity

Uridine fully abrogated the adverse effects of zalcitabine on hepatocyte proliferation and normalized lactate synthesis, intracellular lipids and COX II levels. We calculated specific and overall adverse event rates from use of zidovudine, didanosine, zal citabine, cotrimoxazole, and dapsone in an observational urban cohort.

ExcerptReferenceRelevance
"The most commonly reported adverse event was headache, which was generally reported to be mild."( The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R, 1992
)
0.28
" DDI was mildly toxic to the bone marrow progenitors, with IC50 values of 62 mumol/l for CFU-GM and 70 mumol/l for CFU-E."( Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation.
Boon, GD; Chan, TC; Redmond, R; Shaffer, L, 1992
)
0.28
" Additional male rats and female mice that were treated with 0, 250, 1000, or 2000 mg/kg ddC and male and female mice treated with 0, 50, 400, 1000 mg/kg AZT were maintained for 30 days after treatment was stopped (at 94 days) to evaluate the reversibility of toxic effects."( Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice.
Dunnick, JK; Giles, HD; Irwin, RD; Prejean, JD; Sutphin, ME; Thompson, MB, 1991
)
0.28
" Results reported here show a toxic activity of ddc but further studies are required to ascertain whether this toxicity is of significance during clinical application."( Dideoxycytidine toxicity on mouse hemopoietic progenitors.
Bogliolo, G; Flego, G; Gasparini, L; Lerza, R; Mencoboni, M; Pannacciulli, I,
)
0.13
" The studies discussed here indicate that low-dose ddC treatment regimens substantially reduce the toxic side effects of this drug, and yet retain the ability to affect p24 antigen and CD4+ lymphocyte levels."( Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute
Merigan, TC; Skowron, G, 1990
)
0.28
" Since there are very limited published animal toxicity data available, and nucleoside analogues are being considered for treatment of HIV-infected pregnant women, a study was conducted in mice to investigate the potential adverse developmental effects of this drug."( Developmental toxicity of orally administered 2',3'-dideoxycytidine in mice.
Dunnick, JK; Harris, M; Hoberman, AM; Lindström, P; Morrissey, RE, 1990
)
0.28
" Clinical trials have shown that the continued therapeutic use of these nucleoside derivatives can be associated with adverse side effects."( A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment.
Blair, PC; Fort, MM; Fuchs, BA; Germolec, DR; Luster, MI; McCay, JA; Munson, AE; Thompson, M; Tomaszewski, JE; White, KL, 1989
)
0.28
" All monkeys treated with a continuous intravenous dose of ddC, which maintained plasma concentrations of ddC at levels known to inhibit SRV-2 in vitro, developed dose-related toxic effects, including leukopenia, anemia, lethargy, and decreased appetite."( Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2.
Blakley, GA; Follis, KE; Tsai, CC; Yarnall, M, 1989
)
0.28
" Although these toxic effects are manifest in many tissues, a common disease mechanism can explain the diverse clinical events."( Mitochondrial toxicity of antiviral drugs.
Dalakas, MC; Lewis, W, 1995
)
0.29
" Their adverse effects mostly involve bone marrow depression (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" Twelve patients withdrew because of adverse events during the 24-week treatment period."( Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L, 1996
)
0.29
"Efficacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects."( Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L, 1996
)
0.29
" Safety was assessed by incidence of adverse clinical events and defined laboratory-measured toxic effects."( Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S, 1996
)
0.29
" No statistically significant differences in incidence or severity of clinically manifested or laboratory-measured toxic effects were noted between treatment groups."( Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S, 1996
)
0.29
"Drug therapies for patients with human immunodeficiency virus (HIV) infection are associated with adverse events that can potentially limit their effectiveness."( Adverse events from drug therapy for human immunodeficiency virus disease.
Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD, 1996
)
0.29
"We calculated specific and overall adverse event rates from use of zidovudine, didanosine, zalcitabine, cotrimoxazole, and dapsone in an observational urban cohort of 1,450 HIV-infected patients with a CD4+ count of 500 cells/mm3 or less."( Adverse events from drug therapy for human immunodeficiency virus disease.
Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD, 1996
)
0.51
"Overall adverse event rates in order of incidence were dapsone, 16."( Adverse events from drug therapy for human immunodeficiency virus disease.
Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD, 1996
)
0.29
" Adverse event rates increase progressively with decline in CD4+ count."( Adverse events from drug therapy for human immunodeficiency virus disease.
Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD, 1996
)
0.29
" If interim results provide convincing evidence of either excessive adverse effects or significant treatment benefit, the DSMB may recommend early termination of the trial to the NIAID and the study investigators."( The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ, 1995
)
0.29
"The protein toxin ricin is one of the most toxic substances known."( Potential chemoprotectant activity of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC) against ricin toxicity in Chinese hamster ovary and macrophage J774A.1 cell cultures.
Hassoun, EA; Stohs, SJ,
)
0.13
" A toxic mitochondrial myopathy can be observed in patients treated with AZT, but not with ddI and ddC."( Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
Ammi-Saïd, M; Barlovatz-Meimon, G; Benbrik, E; Bonavaud, S; Chariot, P; Frisdal, E; Gherardi, R; Rey, C, 1997
)
0.53
" Adverse event rates were 37%, 32%, and 60%, respectively, for the nucleoside, 1-mIU interferon, and 6-mIU interferon combination groups."( Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
Fischl, MA; Holden-Wiltse, J; Meehan, PM; Meng, TC; Richman, DD; Saag, M; Squires, KE, 1997
)
0.53
" A total of 332 (49%) HCWs reported at least one adverse effect; 132 (20%) discontinued prophylaxis because of side effects (40% of those reporting side effects)."( Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis.
Ippolito, G; Puro, V, 1997
)
0.3
" Participants were regularly assessed for adverse experiences, changes in laboratory values and clinical progression."( Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Harris, R; Kellagher, A; Moyle, GJ; Walker, M; Warburg, M, 1996
)
0.6
" In cell culture (-)3TC is less toxic than its d(+) isomer, (+)3TC, containing the natural nucleoside configuration, and both are considerably less toxic than ddC."( Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs.
Anderson, KS; Feng, JY; Johnson, AA; Johnson, KA, 2001
)
0.31
"Based on the structure of dideoxycytidine (ddc), the toxic effects of nitroso, areneimine, epoxide, hydroxyl free radical (*OH) and calcium chelating propensity respectively were evaluated using theoretical mechanistic biochemistry techniques."( Theoretical mechanistic basis of the toxic effects and efficacy of dideoxycytidine in HIV:AIDS.
Akintonwa, DA, 2001
)
0.31
" In cell culture, (-)3TC is less toxic than its D (+) isomer, (+)3TC, containing the natural nucleoside configuration, and both are considerably less toxic than 2',3'-dideoxycytidine (ddC)."( Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson, KS, 2002
)
0.31
" Uridine fully abrogated the adverse effects of zalcitabine on hepatocyte proliferation and normalized lactate synthesis, intracellular lipids and COX II levels by adjusting mtDNA levels to about 65% of NRTI-unexposed control cells."( Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.
Koch, EC; Olschewski, M; Schneider, J; Setzer, B; Venhoff, N; Walker, UA, 2003
)
0.57
" Serious adverse events in the two groups were not observed."( Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Dettrairat, S; Klinbuayaem, V; Kunachiwa, W; Leechanachai, P; Leenasirimakul, P; Sangkitporn, S; Shide, L; Thamlikitkul, V; Wirayutwatthana, NA, 2005
)
0.6
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Mitocnol attenuated or normalized all myocardial pathology when given with both NRTI, but by itself had no intrinsic effects and no apparent adverse effects."( Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors.
Balcarek, K; Beauvoit, B; Bonnet, J; Deveaud, C; Kirschner, J; Lebrecht, D; Venhoff, AC; Venhoff, N; Walker, UA, 2010
)
0.36
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43

Pharmacokinetics

No significant differences were found between the pre- and post-partum systemic plasma clearance, steady-state volume of distribution or terminal plasma half-life. In the presence of zalcitabine, the only statistically significant change in the pharmacokinetic parameters of ganciclovir was a 22.5ml/min increase.

ExcerptReferenceRelevance
"A pharmacokinetic evaluation of a potential drug interaction between zidovudine (AZT) and dideoxycytidine (ddC) was conducted in monkeys."( Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
Gallo, JM; Mehta, M; Qian, MX; Swagler, AR; Vishwanathan, CT, 1992
)
0.28
" Pharmacokinetic parameters for ddC and ST4 were calculated based on plasma and urine concentrations of ddC and plasma concentrations of ST4."( Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
Crysler, CS; Fong, KL; Gallo, JM; Mehta, M; Qian, M; Swagler, AR,
)
0.13
" Data were analysed by noncompartmental methods to obtain pharmacokinetic parameters for each drug."( Pharmacokinetics of anti-HIV nucleosides in microswine.
Gallo, JM; Qian, MX; Swagler, AR, 1991
)
0.28
" Non-compartmental pharmacokinetic parameters were calculated by area/moment analysis."( Pharmacokinetics of 2',3'-dideoxycytidine in rats: application to interspecies scale-up.
Boudinot, FD; Ibrahim, SS, 1989
)
0.28
" 3TC concentrations in humans were predicted before the initiation of clinical trials by interspecies scaling of pharmacokinetic parameters observed in animal species."( Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
Daniel, MJ; Donn, KH; Evans, GL; Hall, ST; Harker, AJ; Hussey, EK, 1994
)
0.29
"More than 7 years after the introduction of zidovudine for treatment of HIV infection, little use has been made of the pharmacokinetic properties of this or any of the subsequently approved antiretroviral agents to optimise therapy."( Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Stretcher, BN, 1995
)
0.29
" The published pharmacokinetic data for the nucleoside antiretroviral agents zidovudine, didanosine, zalcitabine, stavudine, and lamivudine show that administration of fixed doses of certain agents results in a considerable degree of between-patient variability in in vivo drug exposure."( Clinical pharmacokinetics of nucleoside antiretroviral agents.
Dudley, MN, 1995
)
0.51
" Pharmacokinetic parameters were generated by area/moment analysis."( Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats.
Abobo, CV; Boudinot, FD; Liotta, DC; Ni, L; Schinazi, RF, 1994
)
0.29
" Lamivudine has entered initial clinical trials, and the present study was designed to describe the pharmacokinetic behavior of this compound in both plasma and cerebrospinal fluid (CSF) of primates."( Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates.
Balis, FM; Blaney, SM; Daniel, MJ; Godwin, K; Harker, AJ, 1995
)
0.29
" Approximately 100 patients were enrolled in each treatment arm, and intensive pharmacokinetic studies were performed on about 25 patients per arm at weeks 1 and 12."( Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
Blaschke, TF; Collier, AC; Gries, JM; Kastrissios, H; Park, K; Sheiner, LB; Squires, K; Vanhove, GF; Verotta, D, 1997
)
0.55
" No significant differences were found between the pre- and post-partum systemic plasma clearance, steady-state volume of distribution or terminal plasma half-life of zalcitabine, indicating that pregnancy does not affect the pharmacokinetics of the drug in the macaque."( Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina).
Nosbisch, C; Tuntland, T; Unadkat, JD, 1997
)
0.71
" Except renal clearance (CIR), there were no statistically significant differences in the pharmacokinetic parameters including the steady-state volume of distribution and distribution coefficient."( Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats.
Abobo, CV; Xian, Y, 1997
)
0.54
"5 ml/min), were entered into NONMEM to obtain population estimates for zalcitabine pharmacokinetic parameters."( Zalcitabine population pharmacokinetics: application of radioimmunoassay.
Adams, JM; DeRemer, M; DiFrancesco, R; Grasela, TH; Hewitt, RG; Morse, GD; Shelton, MJ, 1998
)
1.98
" Owing to dose-related toxicities associated with these two drugs, it is essential that we have data regarding their pharmacokinetic disposition during concomitant therapy."( Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
Aweeka, FT; Botwin, K; Brody, SR; Jacobson, M; Martin-Munley, S,
)
0.37
" No statistically significant differences were observed between the three groups in maximum concentration (Cmax), time to Cmax (tmax), or volume of distribution (V/F)."( The effects of renal impairment on the pharmacokinetics of zalcitabine.
Bazunga, M; Chow, MS; Kertland, H; Massarella, J; Tran, HT, 1998
)
0.54
" The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle."( Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.
Borg, N; Ståhle, L, 1998
)
0.54
"The values of the pharmacokinetic parameters of the nucleoside antiretroviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D-D4FC) in rhesus monkeys were determined with a two-compartment model after the administration of a single dose."( Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
Hurwitz, SJ; Liotta, DC; Ma, L; Mcatee, JJ; McClure, HM; Schinazi, RF; Shi, J, 1999
)
0.3
" Pharmacokinetic parameters were obtained on the basis of a two-compartment open model with a first-order elimination from the central compartment."( Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
Cretton-Scott, E; Gosselin, G; Imbach, JL; Martin, LT; Mathe, C; McClure, HM; Schinazi, RF; Sommadossi, JP; Zhou, XJ, 1999
)
0.3
" In the presence of zalcitabine, the only statistically significant change in the pharmacokinetic parameters of ganciclovir was a 22."( The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients.
AbdelHameed, MH; Dorr, A; Griffy, K; Jung, D; Teitelbaum, P, 1999
)
0.86
" Plasma concentrations declined in a biexponential fashion with an average beta half-life of 12."( Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.
Asif, G; Chu, CK; Gumina, G; Hurwitz, SJ; McClure, HM; Schinazi, RF, 2005
)
0.33
" Plasma concentrations from a group of 54 rats, 12 pregnant rabbits and 60 dogs enrolled in large toxicity studies using a wide variety of oral doses, were compared using non-compartment pharmacokinetic modelling versus dose, treatment duration, species and gender."( Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
Hurwitz, SJ; Otto, MJ; Schinazi, RF, 2005
)
0.33
" Pharmacokinetic parameters were dose proportional, and the maximum concentration of drug in serum at all doses exceeded the 90% effective concentration for wild-type HIV-1."( Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H, 2005
)
0.33
"To investigate the pharmacokinetic interactions between zalcitabine and nonsteroidal anti-inflammatory drugs (NSAIDs) in rats."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
0.87
"Zalcitabine was administered to rats via an iv injection (20 mg/kg) in the presence or absence of ketoprofen or naproxen (20 mg/kg), and the pharmacokinetic parameters were determined by using non-compartmental analysis."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
2.07
"Compared with the control (zalcitabine alone), pretreatment with ketoprofen or naproxen 30 min prior to intravenous administration of zalcitabine significantly altered the pharmacokinetic profiles of zalcitabine in rats."( Altered pharmacokinetics of zalcitabine by concurrent use of NSAIDs in rats.
Han, HK; Oh, YH, 2006
)
0.92
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The pharmacokinetic behavior of elvucitabine was best described by a two-compartment linear model using two absorption rates and a first-order elimination rate."( Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
Colucci, P; Ducharme, MP; Pottage, JC; Robison, H; Turgeon, J, 2009
)
0.35

Compound-Compound Interactions

A randomized double blind placebo controlled trial to determine the efficacy and safety of combined-herbs (SH) given with zidovudine (ZDV) and zalcitabine (ddC) for the treatment of HIV infection in Thai adults was conducted in 3 hospitals in northern Thailand during 2002 to 2003.

ExcerptReferenceRelevance
"The present studies examine whether immune-associated toxicities develop in rodents exposed to recombinant human interferon-alpha A/D (rHuIFN-alpha) alone or in combination with anti-retroviral nucleoside analogs."( Immune-associated toxicities induced by in vivo and in vitro exposure to interferon-alpha alone or in combination with nucleoside analogs.
Germolec, DR; Luster, MI; Powell-Oliver, FE; Rosenthal, GJ; Sanders, VM, 1991
)
0.28
" The effects of 3'-azido-3'-deoxythymidine (AZT), alone or in combination with ddCyd, on cell growth, DNA precursor pools, and accumulation of ddCTP were also studied."( 2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.
Eriksson, S; Törnevik, Y, 1990
)
0.28
" To provide a rationale for combination therapy with a second-generation bisheteroarylpiperazine, we investigated the effect of U-90152 in combination with 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxycytidine (ddC)."( Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong, KT; Hinshaw, RR; Pagano, PJ, 1994
)
0.29
" MKC-442 was evaluated in combination with the nucleoside analogues AZT, ddI and ddC, the non-nucleoside RT inhibitor nevirapine, the HIV-1 proteinase inhibitor Ro-31-8959, and the alpha-glucosidase 1 inhibitor, MDL-28,574, using a cell viability assay."( The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS, 1995
)
0.29
" They must be administered with caution during pregnancy, because some are known teratogens (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" The ability of ISIS 2922 to inhibit replication of HCMV when used in combination with other antiviral agents approved for treatment of HCMV disease was investigated using a 96-well immunoassay."( Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW, 1995
)
0.29
" When 3TC was combined with TSAO-m3T, UC10, UC42, BHAP, or MKC-442, breakthrough of virus was markedly delayed or even suppressed."( Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini, J; Camarasa, MJ; De Clercq, E; Karlsson, A; Pelemans, H; Pérez-Pérez, MJ; San-Félix, A, 1996
)
0.29
"A total of 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter were randomly assigned to receive zidovudine alone or zidovudine combined with either didanosine or zalcitabine."( Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Rese
Abrams, D; Collins, G; Crane, L; Hodges, JS; Loveless, MO; Markowitz, N; Pettinelli, C; Reves, R; Saravolatz, LD; Stein, DS; Thompson, M; Winslow, DL, 1996
)
0.73
" Additive antiviral activity was observed with L(-)Fd4C in combination with 2',3'-dideoxycytidine (ddC, or zalcitabine) or 2',3'-dideoxyinosine (ddI, or didanosine)."( Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Bridges, EG; Cheng, YC; Dutschman, GE; Gullen, E; Guo, X; Kukhanova, M; Liu, SH, 1998
)
0.51
" We used the drug either alone or in double and triple combination with AZT and ddC to assess whether SQV enhances the immunomodulatory effects induced by AZT and ddC that we previously observed."( Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.
Boirivant, M; Camponeschi, B; Di Genova, G; Quaranta, MG; Viora, M, 1998
)
0.3
" Similar antiviral activity was demonstrated when ddI was combined with 5 or 10 mM RV in PBMCs infected with clinical isolates of HIV-1."( Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Davis, C; Heredia, A; Redfield, R, 2000
)
0.31
" We used the drug alone or in double and triple combination with AZT and ddC to assess whether IDV interferes with the previously observed immunomodulatory effects induced by AZT and ddC."( Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions.
Giordani, L; Mattioli, B; Quaranta, MG; Viora, M, 2004
)
0.32
"A randomized double blind placebo controlled trial to determine the efficacy and safety of combined-herbs (SH) given with zidovudine (ZDV) and zalcitabine (ddC) for the treatment of HIV infection in Thai adults was conducted in 3 hospitals in northern Thailand during 2002 to 2003."( Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Dettrairat, S; Klinbuayaem, V; Kunachiwa, W; Leechanachai, P; Leenasirimakul, P; Sangkitporn, S; Shide, L; Thamlikitkul, V; Wirayutwatthana, NA, 2005
)
0.8
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
"Neuropathic pain was induced by peripheral HIV coat protein gp120 combined with 2',3'-dideoxycytidine (ddC, one of the nucleoside reverse transcriptase inhibitors (NRTIs))."( IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats.
Candiotti, KA; Hao, S; Huang, W; Levitt, RC; Liu, S; Lubarsky, DA; Zheng, W, 2014
)
0.4
" In this study, we tested the hypothesis that HIV gp120 combined with antiretroviral therapy reduces spinal GABAergic inhibitory tone and that restoration of GABAergic inhibitory tone will reduce HIV-related NP in a rat model."( Gene Transfer of Glutamic Acid Decarboxylase 67 by Herpes Simplex Virus Vectors Suppresses Neuropathic Pain Induced by Human Immunodeficiency Virus gp120 Combined with ddC in Rats.
Candiotti, KA; Hao, S; Huang, W; Kanao, M; Kanda, H; Levitt, RC; Liu, S; Lubarsky, DA; Yi, H, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The mean bioavailability of 3TC was 82% following oral administration."( The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R, 1992
)
0.28
" Absorption of FTC after oral administration was rapid, with bioavailability averaging 73 +/- 6%."( Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.
Boudinot, FD; Ibrahim, SS; Liotta, DC; Manning, C; McClure, HM; Schinazi, RF, 1992
)
0.28
"2 hours and an oral bioavailability of about 87 percent."( Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.
Broder, S, 1990
)
0.28
"74 h after intravenous and oral administration, respectively, and the oral bioavailability was about 21 percent."( Antiretroviral activity, biochemistry, and pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine.
Boudinot, FD; Chu, CK; Doshi, KJ; Eriksson, BF; McClure, HM; Oswald, B; Schinazi, RF; Sommadossi, JP, 1990
)
0.28
" The bioavailability values calculated for the oral tablets were variable, ranging from 54 to 127%."( A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex.
Dunton, AW; Fukuda, EK; Gustavson, LE; Rubio, FA, 1990
)
0.28
"2 hours, and bioavailability was 88%."( Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
Broder, S; Collins, JM; Klecker, RW; McAtee, N; Myers, CE; Thomas, R; Yarchoan, RC, 1988
)
0.27
" ddC was well absorbed from the gut and crossed the blood-brain barrier."( Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Allain, JP; Dubinsky, R; Fischl, MA; Klecker, RW; McAtee, N; McNeely, MC; Perno, CF; Thomas, RV; Wills, RJ; Yarchoan, R, 1988
)
0.27
" Zalcitabine is well absorbed orally and reaches maximal plasma concentrations within 1 to 2 hours."( Zalcitabine. Clinical pharmacokinetics and efficacy.
Devineni, D; Gallo, JM, 1995
)
2.64
" The pharmacokinetics and bioavailability of 524W91 after oral dosing were studied in mice dosed with 10, 100, and 600 mg of 524W91 per kg of body weight by the oral and intravenous routes."( Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
Frick, LW; Lambe, CU; Nelson, DJ; St John, L; Taylor, LC, 1994
)
0.29
" The drug is stable in gastric pH and has good bioavailability (approximately 70-90 percent), but is rapidly cleared from plasma (half life approximately 1-3 h)."( Zalcitabine.
Morse, GD; O'Donnell, AM; Shelton, MJ, 1993
)
1.73
"1 liters/h/kg, and the oral bioavailability was 90% +/- 8%."( Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
Frick, LW; Furfine, ES; Furman, PA; Liotta, DC; Nelson, DJ; Painter, GR; St John, L; Taylor, LC, 1993
)
0.29
" The mean absolute bioavailability was 50% within a 95% confidence interval of 20 to 80%."( Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus.
Edelman, K; Hooker, M; Muirhead, GJ; Rousseau, FS; Sereni, D; Williams, PE, 1993
)
0.29
" Comparison of plasma AUC values indicated a small (14%) reduction in bioavailability when given with food."( The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients.
Holazo, AA; Limjuco, R; Massarella, JW; Min, B; Nazareno, LA; Passe, S; Twardy, SK, 1995
)
0.56
" Ritonavir has good oral bioavailability, and may increase the bioavailability of other protease inhibitors including saquinavir, nelfinavir, indinavir and VX-478."( Ritonavir.
Faulds, D; Lea, AP, 1996
)
0.29
" The oral bioavailability of D-D4FC averaged 41%."( Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
Hurwitz, SJ; Liotta, DC; Ma, L; Mcatee, JJ; McClure, HM; Schinazi, RF; Shi, J, 1999
)
0.3
" The absolute bioavailability of orally administered beta-L-FddC ranged from 56 to 66%."( Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
Cretton-Scott, E; Gosselin, G; Imbach, JL; Martin, LT; Mathe, C; McClure, HM; Schinazi, RF; Sommadossi, JP; Zhou, XJ, 1999
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" However, two pharmacokinetic problems have been identified: suboptimal oral bioavailability of peptidic inhibitors; and reduced cellular uptake of inhibitor that has become bound to alpha-acid glycoprotein."( Update on HIV protease inhibitors.
Vella, S, 1995
)
0.29
" To determine whether the bioavailability may be improved by using a basic buffer solution, the oral dose was repeated to the same animals in a sodium bicarbonate solution."( Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.
Asif, G; Chu, CK; Gumina, G; Hurwitz, SJ; McClure, HM; Schinazi, RF, 2005
)
0.33
"34 g/kg/d), a dietary supplement with high bioavailability of uridine."( Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
Kirschner, J; Lebrecht, D; Setzer, B; Vargas-Infante, YA; Walker, UA, 2007
)
0.61
" The decrease in elvucitabine bioavailability when elvucitabine was coadministered with ritonavir may be due to ritonavir's inhibiting influx gut transporters."( Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
Colucci, P; Ducharme, MP; Pottage, JC; Robison, H; Turgeon, J, 2009
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"Due to their hydrophilic nature, most nucleoside reverse transcriptase inhibitors (NRTIs) display a variable bioavailability after oral administration and a poor control over their biodistribution, thus hampering their access to HIV sanctuaries."( Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
Andrieux, K; Argote, S; Bauduin, L; Bekkara-Aounallah, F; Caron, J; Clayette, P; Couvreur, P; Dereuddre-Bosquet, N; Desmaële, D; Gref, R; Hillaireau, H; Lepêtre, S; Rogez-Kreuz, C; Rousseau, B; Skanji, R; Yousfi, R, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The pharmacokinetic changes observed in this study are not expected to result in significant accumulation during chronic dosing. If replicated in humans, these substantial age-dependent changes in the pharmacokinetics of zal citabine would warrant smaller and less frequent dosing with zalcitabine in HIV-infected neonates than in older children and adults.

ExcerptRelevanceReference
" Four patients were dosed at each of five dose levels (0."( The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R, 1992
)
0.28
" Each of six animals received 20 mg/kg of AZT intragastrically in the absence and presence of an intravenous steady-state dosage regimen of ddC."( Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
Gallo, JM; Mehta, M; Qian, MX; Swagler, AR; Vishwanathan, CT, 1992
)
0.28
" We evaluated six dosing regimens, each involving oral administration of the study drugs at 8-hour intervals."( Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
Bassiakos, Y; Bennett, D; Boota, AM; Fischl, MA; Lai, SH; Meng, TC; Richman, DD; Spector, SA; Wright, B, 1992
)
0.28
" The kinetic information provides a basis for rational dosage design for combination chemotherapeutic regimens of ddC and ST4 in human immunodeficiency virus infection."( Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
Crysler, CS; Fong, KL; Gallo, JM; Mehta, M; Qian, M; Swagler, AR,
)
0.13
" The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens."( Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991
)
0.28
" To obtain maximum efficacy, combination regimens should include agents that do not share cross-resistance, have different mechanisms of action, and have different dose-limiting toxicities; the relative merits of a concurrent dosage schedule (limits drug failure) and a consecutive dosage schedule (limits toxicity) must also be considered."( Treatment of AIDS with combinations of antiretroviral agents.
Merigan, TC, 1991
)
0.28
" The different toxicity profiles of these two drugs provide the rationale for testing them in alternating dosing combinations in an attempt to retain the antiretroviral activity of each against human immunodeficiency virus, while reducing the toxicities of both."( Alternating and intermittent regimens of zidovudine (3'-azido-3'-deoxythymidine) and dideoxycytidine (2',3'-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
Merigan, TC; Skowron, G, 1990
)
0.28
"In a pilot study, we evaluated four dosage levels of ddC--0."( Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
Balis, F; Brouwers, E; Butler, K; Eddy, J; Einloth, M; Falloon, J; Hawkins, M; Husson, R; Jarosinski, P; Pizzo, PA, 1990
)
0.28
" Longer courses of ddC at lower dosage levels, and schedules integrating ddC into combination regimens, deserve to be explored."( Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection.
Balis, F; Brouwers, E; Butler, K; Eddy, J; Einloth, M; Falloon, J; Hawkins, M; Husson, R; Jarosinski, P; Pizzo, PA, 1990
)
0.28
" We describe here the evaluation of 2',3'-dideoxycytidine (ddC) against FeLV-FAIDS infection - both in vitro in cell culture assay systems and in vivo in cats administered ddC either via intravenous bolus dosage or via controlled release subcutaneous implants."( Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy.
Hill, DL; Hoover, EA; Mullins, JI; Perigo, NA; Quackenbush, SL; Strobel, JD; Zeidner, NS, 1989
)
0.28
" Though ddc has potent activity against HIV-1 in vitro, serious toxic effects seen in phase 1 studies warrant continuation of trials to explore lower dosage regimens, alternation with zidovudine and intermittent therapy."( The antiviral activity of dideoxycytidine.
Jeffries, DJ, 1989
)
0.28
"Four dosing regimens of 2',3'-dideoxycytidine (ddC) were administered intravenously for 10 to 28 days to 18 pigtailed macaques with simian acquired immunodeficiency syndrome."( Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2.
Blakley, GA; Follis, KE; Tsai, CC; Yarnall, M, 1989
)
0.28
"15 cells showed reductions in levels of HBV in serum and in intracellular levels of HBV when the mice were orally dosed with (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC)."( Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.
Condreay, LD; Daluge, SM; Ellis, MN; Furman, PA; Jansen, RW; Johnson, LC; Paff, MT; Painter, GR; Powdrill, TF; Selleseth, DW, 1994
)
0.29
" The concentration-time profile and the average serum concentration at steady state after various dosage regimens were estimated as a basis for initial dose selection for clinical trials."( Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
Daniel, MJ; Donn, KH; Evans, GL; Hall, ST; Harker, AJ; Hussey, EK, 1994
)
0.29
" Measurements of phosphorylated zidovudine inside cells similarly suggest that 100 mg of oral zidovudine every 8 hours approximates the optimal initial dosage regimen in asymptomatic patients."( Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Stretcher, BN, 1995
)
0.29
" The pharmacokinetics and bioavailability of 524W91 after oral dosing were studied in mice dosed with 10, 100, and 600 mg of 524W91 per kg of body weight by the oral and intravenous routes."( Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
Frick, LW; Lambe, CU; Nelson, DJ; St John, L; Taylor, LC, 1994
)
0.29
" DPP-AZT administered intraperitoneally in liposomes as a single daily dose to mice infected with Rauscher leukemia virus prevented increased spleen weight and reverse transcriptase levels in serum with a dose-response roughly comparable to that of AZT given continuously in the drinking water."( Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.
Ellis, MN; Felgner, J; Felgner, PL; Gardner, MF; Hostetler, KY; Ricci, J; Richman, DD; Selleseth, DW; Sridhar, CN, 1994
)
0.29
" There was no consistent dose-response correlation for any surrogate marker."( Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J, 1995
)
0.29
" In addition to an understanding of the recommended dosing guidelines, proper management of AIDS therapy requires a fundamental knowledge of the disease process, the pharmacology and limitations of the agents employed against the virus, and close cooperation with the clinical laboratory."( Management of antiretroviral drug therapy in human immunodeficiency virus infection.
Stretcher, B, 1994
)
0.29
" Overall, 17-31 percent of the patients receiving the currently recommended initial dosage of ddC experience peripheral neuropathy."( Zalcitabine.
Morse, GD; O'Donnell, AM; Shelton, MJ, 1993
)
1.73
" The aim of this study was to estimate an oral dosage regimen of 2FddC giving peak plasma drug concentrations close to the antiretroviral IC50 of 150 ng ml-1."( Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus.
Edelman, K; Hooker, M; Muirhead, GJ; Rousseau, FS; Sereni, D; Williams, PE, 1993
)
0.29
"The problem of optimal dosage is studied for the administration of ddCyd using erythrocytes as carriers and bioreactors."( An optimal time control problem for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.
Beretta, E; Solimano, F, 1993
)
0.29
" Zidovudine is indicated at a dosage varying between 500 and 1000 mg in patients with AIDS and ARC, in asymptomatic patients with CD4 < 200/mm3 and in asymptomatic patients with CD4 between 200 and 500 cells/mm3 with a rapid decrease of CD4 cell count or a positive P24 circulating antigen."( Current use of anti-HIV drugs in AIDS.
Clumeck, N, 1993
)
0.29
"Administration with food delayed and prolonged absorption resulting in a decrease of approximately 39% in maximal plasma concentrations compared to dosing under fasting conditions."( The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients.
Holazo, AA; Limjuco, R; Massarella, JW; Min, B; Nazareno, LA; Passe, S; Twardy, SK, 1995
)
0.56
"To determine the effect of multiple dosing of combined sulfamethoxazole and trimethoprim on the single-dose pharmacokinetics of lamivudine."( Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
Eron, JJ; Hussey, EK; Martin, D; Moore, KH; Mydlow, PK; Raasch, RH; Yuen, GJ, 1996
)
0.29
"Coadministration of a single dose of lamivudine and trimethoprim-sulfamethoxazole after daily dosing for 5 days altered the pharmacokinetics of lamivudine."( Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
Eron, JJ; Hussey, EK; Martin, D; Moore, KH; Mydlow, PK; Raasch, RH; Yuen, GJ, 1996
)
0.29
" Considering the short half-life of zalcitabine (1-3 hours) relative to its dosing schedule, the pharmacokinetic changes observed in this study are not expected to result in significant accumulation during chronic dosing."( The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
Massarella, JW; Min, B; Nazareno, LA; Passe, S, 1996
)
0.82
" Although well tolerated in this single-dose study, patients taking this combination should be monitored closely for signs of toxicity and dosage reduction should be considered if warranted."( The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
Massarella, JW; Min, B; Nazareno, LA; Passe, S, 1996
)
0.54
" If replicated in humans, these substantial age-dependent changes in the pharmacokinetics of zalcitabine would warrant smaller and less frequent dosing with zalcitabine in HIV-infected neonates than in older children and adults."( Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina).
Nosbisch, C; Tuntland, T; Unadkat, JD, 1997
)
0.74
" This period appears to coincide with reduced dosage regimens."( Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats.
Abobo, CV; Xian, Y, 1997
)
0.54
" These data, along with dosing information, age (38."( Zalcitabine population pharmacokinetics: application of radioimmunoassay.
Adams, JM; DeRemer, M; DiFrancesco, R; Grasela, TH; Hewitt, RG; Morse, GD; Shelton, MJ, 1998
)
1.74
" Twelve patients randomly received either foscarnet (four doses) or zalcitabine (five doses) (Phase 1), followed by concomitant foscarnet (four doses) and zalcitabine (six doses) (Phase 2), followed by dosing with the drug not received in Phase 1 (Phase 3)."( Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
Aweeka, FT; Botwin, K; Brody, SR; Jacobson, M; Martin-Munley, S,
)
0.61
" Dosage adjustment may be warranted in such patients, especially in those with severe renal impairment."( The effects of renal impairment on the pharmacokinetics of zalcitabine.
Bazunga, M; Chow, MS; Kertland, H; Massarella, J; Tran, HT, 1998
)
0.54
" Of these, 55, 66 and 79%, respectively, were taken at the prescribed dosing frequency."( Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
Blaschke, TF; Girard, P; Kastrissios, H; Katzenstein, D; Sheiner, LB; Suárez, JR, 1998
)
0.3
"Between October 1992 and January 1994, study sites were selected at random, and a 1-week period was designated during which study participants attending routine clinic visits provided a blood sample and dosing history."( The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.
Blaschke, TF; Hammer, S; Kastrissios, H; Katzenstein, D; Suárez, JR, 1998
)
0.3
" Women reported reducing dosage and discontinue ddI-containing regimens more frequently than men did; adjustment for weight did not completely explain this difference."( Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Cotton, DJ; Currier, JS; Grimes, J; Hammer, SM; Hughes, MD; Katzenstein, DA; Spino, C; Wofsy, CB, 2000
)
0.31
" L(-)I-OddU is the most potent anti-Epstein-Barr Virus (EBV) compound without cytotoxicity and animal toxicity upon long-term dosing which gives the pharmacological levels of the drug in plasma."( Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.
Cheng, YC, 2001
)
0.31
" These results indicate that beta-L-Fd4C exhibits a more potent antiviral effect than lamivudine in the WHV model but was not able to eradicate CCC DNA and infected cells from the liver at the dosage and with the protocol used."( Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Cheng, YC; Chevallier, M; Guerret, S; Hantz, O; Jamard, C; King, I; Le Guerhier, F; Peyrol, S; Pichoud, C; Trépo, C; Zoulim, F, 2001
)
0.31
" Findings from studies for each drug in such areas as the drug's purpose, dosage level, effectiveness, and side effects are examined."( What we know about anti-HIV drugs.
, 1995
)
0.29
" Each drug trial demonstrates the relationship between dosing and resistance; patients are advised to adhere completely to dosing instructions."( Protease inhibitors and prevention of cross resistance.
Levin, J, 1995
)
0.29
" Invirase is also expensive, particularly at the higher dosage levels."( FDA approves 3TC and saquinavir. Food and Drug Administration.
Baker, R, 1995
)
0.29
" A recommended dosage schedule for ddI and d4T combined with indinavir is provided."( ddI and d4T plus protease inhibitors.
, 1996
)
0.29
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."( What they say about: nucleoside drugs.
,
)
0.13
"A HPLC method for zalcitabine determination in bulk form, pharmaceutical dosage forms and human serum has been developed and validated."( Validated RP-hPLC method for the assay of zalcitabine in drug substance, formulated products and human serum.
Ozkan, SA; Ozkan, Y; Savaşer, A; Uslu, B, 2004
)
0.92
" Sequence analysis of the HIV-1 RT gene performed before and after RVT dosing detected no genotypic changes in this short-term study."( Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose.
Beard, A; Cartee, L; De La Rosa, A; Kravec, I; McBrayer, TR; Murphy, RL; Otto, MJ; Schinazi, RF; Schürmann, D; Stuyver, LJ, 2004
)
0.32
" This study highlights the importance of selecting animal species that demonstrate similar cytidine deaminase activity to humans when performing preclinical dosing studies on Racivir and other antiviral agents that are substrates for mammalian cytidine deaminases."( Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans.
Hurwitz, SJ; Otto, MJ; Schinazi, RF, 2005
)
0.33
"36 mg/kg/d of zalcitabine (corresponding to human dosing adapted for body surface), or 13 mg/kg/d of zalcitabine."( Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
Kirschner, J; Lebrecht, D; Setzer, B; Vargas-Infante, YA; Walker, UA, 2007
)
0.98
" Three different dosing regimens of elvucitabine were administered with lopinavir-ritonavir to 24 subjects with moderate levels of HIV."( Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J, 2009
)
0.35
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
HIV-1 reverse transcriptase inhibitorAn entity which inhibits the activity of HIV-1 reverse transcriptase.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidine 2',3'-dideoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Zalcitabine Action Pathway05

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.34170.003245.467312,589.2998AID2517
thioredoxin reductaseRattus norvegicus (Norway rat)Potency10.45580.100020.879379.4328AID488773; AID588453; AID588456
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.49150.006038.004119,952.5996AID1159521
NFKB1 protein, partialHomo sapiens (human)Potency0.79430.02827.055915.8489AID895; AID928
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency10.36060.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency0.12590.180013.557439.8107AID1468
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.85900.001022.650876.6163AID1224838
EWS/FLI fusion proteinHomo sapiens (human)Potency0.00120.001310.157742.8575AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.67620.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency61.64480.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency60.07530.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency60.07530.005428.02631,258.9301AID1346982
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency27.05800.023723.228263.5986AID743222
Bloom syndrome protein isoform 1Homo sapiens (human)Potency199.52600.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency22.38720.010039.53711,122.0200AID588545
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.10000.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency10.00000.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Ki0.05100.00031.552310.0000AID238445
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd44.00000.08933.31358.0000AID1238542
C-X-C chemokine receptor type 4Homo sapiens (human)EC50 (µMol)0.08800.00030.04410.0880AID104272
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.03100.00040.61539.7000AID45026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 7Rattus norvegicus (Norway rat)Km3,000.00000.36600.39000.4140AID678818
Reverse transcriptase/RNaseH Human immunodeficiency virus 1CC5034.00000.10000.10000.1000AID45022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (94)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
pyrimidine nucleotide metabolic processDeoxycytidine kinaseHomo sapiens (human)
CMP biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
dAMP salvageDeoxycytidine kinaseHomo sapiens (human)
nucleoside phosphate biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 4Homo sapiens (human)
response to hypoxiaC-X-C chemokine receptor type 4Homo sapiens (human)
neuron migrationC-X-C chemokine receptor type 4Homo sapiens (human)
epithelial cell developmentC-X-C chemokine receptor type 4Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
apoptotic processC-X-C chemokine receptor type 4Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
neuron recognitionC-X-C chemokine receptor type 4Homo sapiens (human)
response to virusC-X-C chemokine receptor type 4Homo sapiens (human)
response to activityC-X-C chemokine receptor type 4Homo sapiens (human)
telencephalon cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of cell adhesionC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of vascular wound healingC-X-C chemokine receptor type 4Homo sapiens (human)
CXCL12-activated CXCR4 signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of programmed cell deathC-X-C chemokine receptor type 4Homo sapiens (human)
myelin maintenanceC-X-C chemokine receptor type 4Homo sapiens (human)
endothelial cell differentiationC-X-C chemokine receptor type 4Homo sapiens (human)
symbiont entry into host cellC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of oligodendrocyte differentiationC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of viral processC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painC-X-C chemokine receptor type 4Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of calcium ion transportC-X-C chemokine receptor type 4Homo sapiens (human)
cardiac muscle contractionC-X-C chemokine receptor type 4Homo sapiens (human)
endothelial tube morphogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to cytokine stimulusC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to organonitrogen compoundC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to xenobiotic stimulusC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
response to tacrolimusC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of dendrite extensionC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of vasculature developmentC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of mesenchymal stem cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
response to ultrasoundC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of macrophage migration inhibitory factor signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
neurogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
cell chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 4Homo sapiens (human)
immune responseC-X-C chemokine receptor type 4Homo sapiens (human)
brain developmentC-X-C chemokine receptor type 4Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 4Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
deoxyadenosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxycytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxyguanosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
ATP bindingDeoxycytidine kinaseHomo sapiens (human)
protein homodimerization activityDeoxycytidine kinaseHomo sapiens (human)
cytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
virus receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
actin bindingC-X-C chemokine receptor type 4Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 4Homo sapiens (human)
coreceptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 4Homo sapiens (human)
ubiquitin protein ligase bindingC-X-C chemokine receptor type 4Homo sapiens (human)
myosin light chain bindingC-X-C chemokine receptor type 4Homo sapiens (human)
small molecule bindingC-X-C chemokine receptor type 4Homo sapiens (human)
C-X-C motif chemokine 12 receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
ubiquitin bindingC-X-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nucleoplasmDeoxycytidine kinaseHomo sapiens (human)
cytosolDeoxycytidine kinaseHomo sapiens (human)
mitochondrionDeoxycytidine kinaseHomo sapiens (human)
cytoplasmDeoxycytidine kinaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
lysosomeC-X-C chemokine receptor type 4Homo sapiens (human)
early endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
cytoplasmC-X-C chemokine receptor type 4Homo sapiens (human)
lysosomeC-X-C chemokine receptor type 4Homo sapiens (human)
early endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
late endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 4Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 4Homo sapiens (human)
cell leading edgeC-X-C chemokine receptor type 4Homo sapiens (human)
cytoplasmic vesicleC-X-C chemokine receptor type 4Homo sapiens (human)
extracellular exosomeC-X-C chemokine receptor type 4Homo sapiens (human)
anchoring junctionC-X-C chemokine receptor type 4Homo sapiens (human)
protein-containing complexC-X-C chemokine receptor type 4Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 4Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (515)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1757995Selectivity index, ratio of CC50 for human CEM-TK(-) cells to EC50 for antiviral activity against HIV-1 infected in human CEM-TK(-) cells2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID234204Therapeutic index (Ratio = ID50/ED50).1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID45022Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID32366Percent protection of ATH8 cells from HIV-induced cytopathic effects at a concentration of 1 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID397589Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID46438Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID46243Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID718370Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID1238542Binding affinity to human serum albumin with excitation at 280 nm after 2 hrs by spectrofluorimetric analysis2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
AID91247Inhibitory concentration against hepatitis B virus infected 2.2.15 cells1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.
AID1757998Selectivity index, ratio of CC50 for human CEM-TK(-) cells to EC50 for antiviral activity against HIV-1 infected in human CEM-TK(-) cells in presence of AZT2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1757991Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID235704Selectivity index of CD50 to ED50 of MT-4 cells1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID104455Growth inhibition of HIV-1 in human lymphocyte MT-4 cells1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine.
AID43709In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
AID717259Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID152976Effective concentration to inhibit HIV-1 LAI cytopathicity in PBMC cells was determined in vitro; Not determined2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID47309Cytotoxicity on CEM cells1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.
AID104577Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID104458Inhibitory concentration determined on an HIV infection model mediated by CXCR4; Not tested2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID1757982Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID233707Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 0.05(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID1068977Antiviral activity against HIV-2 ROD infected in human CEM/0 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID249057Cytotoxicity against MT-2 cell lines of human2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID22063Time dependent concentration level in plasma following 23 mg/kg intravenous administration to rats1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine.
AID604319Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
AID397592Therapeutic index, ratio of cytotoxicity against human H9 cells to EC50 for HIV1 RF2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID32220Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID152968Concentration required to cause death of PBMC cells was determined in vitro; Not determined2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID718369Selectivity index, ratio of CC50 for HIV1 3B infected in human MT4 cells to EC50 for HIV1 3B2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID405349Toxicity in human H9c2 cells assessed as effect on cell viability at 1 to 5 uM after 12 days2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID46434Compound was evaluated for the antiviral activity against HIV-2 strain ROD in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID141779Inhibitory activity on moloney murine leukemia retrovirus.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Anti-HIV-I activity of linked lexitropsins.
AID32065Protection of ATH8 cells against the cytopathic effect of HIV.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID1757986Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV-1 infected in human MT4 cells2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID154933Effective conc. required to achieve 50% inhibition of HIV-2 D194 multiplication in PBM (peripheral blood mononuclear) cells2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID105400AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID24918Half life of DCC in plasma1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine.
AID246469Effective concentration to inhibit 50 % of epstein Barr virus replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1757981Antiviral activity against HIV-1 infected in human CEM-SS cells assessed as reduction in viral multiplication by measuring decrease in reverse transcriptase activity incubated for 5 days in presence of ddA2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1614368Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID45534Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
AID1757997Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID106768Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID1614367Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level at 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID1068976Cytotoxicity against human CEM/0 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID1757977Selectivity index, ratio of CC50 for human CEM-SS cells to EC50 for antiviral activity against HIV-1 infected in human CEM-SS cells2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1757979Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID233701Selectivity ratio to IC50 of MT4 cells and EC50, anti-HIV activity of MT-4 cells1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID1068979Antiviral activity against HIV-2 ROD infected in human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID781025Cytotoxicity against human MT4 cells after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID1203826Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 50 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235634Selectivity index is the ratio of CC50/EC501989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID105319Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID32245Percent cytotoxicity against ATH8 cells at a concentration of 5 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID584625Toxicity in human subcutaneous preadipocytes assessed as triacylglyceride droplets at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID235224Therapeutic index against HIV-1 strain SK1 in CEM-SS cells was expressed as IC50/EC501998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID781024Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID106948Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
AID583453Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex II activity at 10 uM after 15 days relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID334754Ratio of ID50 for cat CRFK cells to ED50 for Feline leukemia virus1992Journal of natural products, Apr, Volume: 55, Issue:4
Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.
AID104237Therapeutic index is the ratio between IC50/EC50 of HIV-I H112-2 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID1498130Cytotoxicity against HEL cells assessed as alteration of cell morphology by microscopic analysis2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID105756Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID583448Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial DNA content at 10 uM after 15 days by RT-PCR method relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID1204872Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesquiterpenoid tropolone glycosides from Liriosma ovata.
AID105205Potency against non nucleoside reverse transcriptor was determined in MT-4 cells2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
AID583435Cytotoxicity against human HepG2 cells assessed as reduction in viable cells at 10 uM after 15 days by trypan blue dye exclusion assay relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID235222Therapeutic index against HIV-1 strain IIIB in CEM-SS cells was expressed as IC50/EC501998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID583454Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex III activity at 10 uM after 15 days relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID1325061Cytotoxicity against HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.
AID233700Selectivity ratio to IC50 of HL60 cells and EC50, anti-HIV activity of MT-4 cells1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID334753Antiviral activity against Feline leukemia virus infected in cat CRFK cells assessed as inhibition of viral replication after 7 days by ELISA1992Journal of natural products, Apr, Volume: 55, Issue:4
Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.
AID42390Antiviral activity against HIV-1 (RF strain) in C8166 cells1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).
AID1757992Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV-1 infected in human MT4 cells in presence of ddA2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID105764Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID732812Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID572769Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID88976The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
AID1204873Cytotoxicity against human CEM-SS cells assessed as cell growth inhibition2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesquiterpenoid tropolone glycosides from Liriosma ovata.
AID584624Toxicity in human subcutaneous preadipocytes assessed as acquisition of adipocyte shape at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1757975Antiviral activity against HIV-1 infected in human CEM-SS cells assessed as reduction in viral multiplication by measuring decrease in reverse transcriptase activity incubated for 5 days2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1203823Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID405337Toxicity against human HepG2/C3A cells assessed as inhibition of cell proliferation at 50 uM after 6 days by SRB assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID32221Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 0.05(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID46940Therapeutic index is the ratio between IC50/EC50 of HIV-I RFII strain in CEM cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID619631Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID105766Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID235481Selectivity index is the ratio of CC50 to EC50 values2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID1614323Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID32223Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 0.5(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID405355Toxicity against human HepG2/C3A cells assessed as reduction in mitochondrial DNA copy numbers at 5 uM after 14 days relative to control2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29358pKa value of the compound.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.
AID781026Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID83249Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.
AID665549Cytotoxicity against human MT4 cells after 5 days by MTT assay2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID197658Concentration that reduces Rauscher murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID235678Selectivity Index measured as ratio of CC50 to that of EC50.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
AID252592Percent of CHO cells with chromosomal aberrations were determined at 10000 uM compound after 20 hr of treatment (harvested at 20h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID232752Selectivity index is the ratio of CC50 to that of EC50 (anti-hepatitis B virus activity in intracellular DNA)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1068978Cytotoxicity against human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID46241Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID648421Cytotoxicity against human MT4 cells after 5 days by MTT assay2012European journal of medicinal chemistry, May, Volume: 51Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID106912The compound was tested for antiviral activity against HIV-1 in MT-2 cells1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
AID104235Therapeutic index is the ratio between IC50/EC50 of HIV-I A17 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID246536Effective concentration to inhibit 50 % of herpes simplex virus type 2 replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID681387TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID572768Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID405352Toxicity against human HepG2/C3A cells assessed as reduction in mitochondrial DNA copy numbers at 1 uM after 4 days relative to control2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID89525Compound was tested in vitro against extracellular DNA hepatitis B virus of human liver cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID1203824Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 1 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID56583Inhibitory affect against rabbit deoxycytidine kinase1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID106892Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID718368Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID648422Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2012European journal of medicinal chemistry, May, Volume: 51Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID732811Cytotoxicity against human MT4 cells by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID685333Cytotoxicity against mock-infected human MT4 cells by MTT assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID142441Cytotoxicity was evaluated1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID32239Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 50(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID614140Cytotoxicity against human MT4 cells after 4 days by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID584810Inhibition of electron transport protein complex 2/3 in human subcutaneous preadipocytes at 0.1 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID32237Compound was evaluated for cytotoxicity by HIV cytopathic effect assay performed with ATH8 cells at a concentration of 5(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1757996Antiviral activity against HIV-1 infected in human CEM-TK(-) cells assessed as reduction in viral multiplication by measuring decrease in reverse transcriptase activity incubated for 6 days in presence of AZT2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1204871Inhibition of human immunodeficiency virus-1 reverse transcriptase associated RNase H activity using using 18-nucleotide 3,-fluorescein-labeled RNA substrate by fluorescence resonance energy transfer assay2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Sesquiterpenoid tropolone glycosides from Liriosma ovata.
AID619633Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-2 ROD infected in human MT4 cells2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID297672Antimycobacterial activity against Mycobacterium tuberculosis H37Ra at 100 uM by microplate alamar blue assay2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.
AID83415Concentration required to inhibit 50% of HIV-IIIB virus replication; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID246456Effective concentration to inhibit 50 % of hepatitis C virus replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID361401Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay2002Journal of natural products, Nov, Volume: 65, Issue:11
New saponins from the starfish Certonardoa semiregularis.
AID1449516Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID89529Compound was tested in vitro against intracellular DNA hepatitis B virus of human liver cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID1449528Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID297676Antimycobacterial activity against Mycobacterium bovis BCG at 100 uM by microplate alamar blue assay2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.
AID1304403Cytotoxicity against mock-infected human MT4 cells2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID106965Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-11989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID405348Toxicity against human HepG2/C3A cells assessed as induction of cell death at 5 uM after 14 days2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID584628Toxicity in human subcutaneous preadipocytes assessed as cell death at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID104236Therapeutic index is the ratio between IC50/EC50 of HIV-I G910-6 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID249723Effect of compound (10000 uM) on growth of CHO cells measured as population doublings from the beginning of the experiment as percent of controls after 20 hr of treatment (harvested at 20h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID47434Inhibitory concentration against mitochondrial DNA synthesis CEM cells1998Journal of medicinal chemistry, Jan-01, Volume: 41, Issue:1
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.
AID1757987Antiviral activity against HIV-1 infected in human MT4 cells assessed as reduction in virus-indued cytopathogenicity incubated for 5 days in presence of AZT by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID200435The compound was tested for the antiviral activity against Rauscher murine leukemia virus1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.
AID665548Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID604320Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV2 ROD2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
AID47425Effect on HIV-induced cytopathogenesis in CEM cells.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID106917Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232751Selectivity index is the ratio of CC50 to that of EC50 (anti-hepatitis B virus activity in extracellular DNA)1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID46239Compound was evaluated for the antiviral activity against HIV-2 strain ROD in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID32365Percent protection of ATH8 cells from HIV-induced cytopathic effects at a concentration of 0.5 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID89524Tested for in vitro cytotoxic concentration against hepatitis B irus replication in chronically HBV-producing human liver cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID584607Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA abundance at 0.1 uM after 60 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID32367Percent protection of ATH8 cells from HIV-induced cytopathic effects at a concentration of 5 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID32243Percent cytotoxicity against ATH8 cells at a concentration of 0.5 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID106428In vitro antiviral activity against HIV-1 in MT-4 Cell1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and anti-HIV activity of 9-[c-4,t-5-bis(hydroxymethyl)cyclopent-2-en-r-1-yl]-9H-adenine.
AID106599Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID216007Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID106598Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID106891Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID232768Selectivity index of IC50 and CD50 of the compound1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).
AID648420Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay2012European journal of medicinal chemistry, May, Volume: 51Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID246455Effective concentration to inhibit 50 % of hepatitis B virus replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID26769Partition coefficient (logP)1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID106890Anti-HIV activity against HIV-I A17 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID106749Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
AID125177In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
AID3000Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1322997Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID22062Time dependent concentration level in brain following 23 mg/kg intravenous administration to rats1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine.
AID1323000Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID1610167Antiviral activity against Human adenovirus 2 infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID584812Inhibition of electron transport protein complex 5 in human subcutaneous preadipocytes at 0.1 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID105590Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID779529Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID1449529Mitochondrial toxicity in human HepG2 cells assessed as cytochrome c oxidase subunit 2 DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID104264Inhibitory concentration that reduces formazan production in infected MT-2 cells.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.
AID46237Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID154948Cytotoxic concentration of compound determined by the tyran blue exclusion staining method in PBMC by test II; Not tested2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID47612Minimum compound concentration that reduced cell viability by 25% for HIV replication in CEM cells.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID104256Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID1449524Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels at 10 uM measured on day 14 by RT-PCR method relative to nuclear beta-actin DNA levels2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1757980Selectivity index, ratio of CC50 for human CEM-SS cells to EC50 for antiviral activity against HIV-1 infected in human CEM-SS cells in presence of AZT2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID106893Anti-HIV activity against HIV-I IIIB strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID47455Antiviral test was performed against HIV (LAV strain) on CEM cells using 50 tissue culture infectious units.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.
AID1614322Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID732810Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition.
AID46007Anti-HIV activity against HIV-I RFII strain in CEM cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID718371Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID397590Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID685331Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID584629Toxicity in fully differentiated human subcutaneous preadipocytes assessed as cell death at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID405353Toxicity against human HepG2/C3A cells assessed as reduction in mitochondrial DNA copy numbers at 5 uM after 4 days relative to control2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID397591Therapeutic index, ratio of cytotoxicity against human H9 cells to EC50 for HIV1 3B2001Journal of natural products, Feb, Volume: 64, Issue:2
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID583452Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex I activity at 10 uM after 15 days relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID619632Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID104310Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID80886Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB). 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
AID233709Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 0.5(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID584819Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial mass at 0.1 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID246535Effective concentration to inhibit 50 % of herpes simplex virus type 1 replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1757978Antiviral activity against HIV-1 infected in human CEM-SS cells assessed as reduction in viral multiplication by measuring decrease in reverse transcriptase activity incubated for 5 days in presence of AZT2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1757984Antiviral activity against HIV-1 infected in human MT4 cells assessed as reduction in virus-indued cytopathogenicity incubated for 5 days by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID361400Cytotoxicity against human MT4 cells after 5 days by MTT assay2002Journal of natural products, Nov, Volume: 65, Issue:11
New saponins from the starfish Certonardoa semiregularis.
AID235225Therapeutic index against HIV-2 strain ROD in CEM-SS cells was expressed as IC50/EC501998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID32219Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID217738Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.
AID1270865Inhibition of human DNA polymerase-beta expressed in wild-type 92TAg cells assessed as increase in MMS toxicity at 1 uM incubated for 2 hrs prior to MMS challenge for 2 hrs followed by post wash compound addition measured after 24 hrs by MTT assay2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Identification of 5-Methoxyflavone as a Novel DNA Polymerase-Beta Inhibitor and Neuroprotective Agent against Beta-Amyloid Toxicity.
AID32364Percent protection of ATH8 cells from HIV-induced cytopathic effects at a concentration of 0.2 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID584630Toxicity in human subcutaneous preadipocytes assessed as decrease of PPARgamma expression at 0.1 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID572991Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 10 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID665547Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID84773Concentration required to inhibit 50% of HSV-2 replication; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID1072800Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID106916Anti-HIV activity against HIV-I A17 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID246491Effective concentration to inhibit 50% of cytomegalovirus (CMV) replication in a cell culture model;ND=Not determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID232747Selectivity index is calculated by dividing the TC25(MT2) by ID50(MT2)1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID717261Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID104238Therapeutic index is the ratio between IC50/EC50 of HIV-I IIIB strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID392501Antiviral activity against Human adenovirus 22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1068980Antiviral activity against HIV-1 3B infected in human MT4 cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID1757994Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID89527Compound was tested in vitro against intracellular DNA hepatitis B virus of human liver cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID246416Effective concentration to inhibit 50% of human immunodeficiency virus replication in a cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID106427In vitro antiviral activity against HIV-1 in MT-4 Cell1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and anti-HIV activity of 9-[c-4,t-5-bis(hydroxymethyl)cyclopent-2-en-r-1-yl]-9H-adenine.
AID614143Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID779528Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID235683Selectivity Index measured as the ratio of EC50 to that of CC50 values.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
AID1449527Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID405354Toxicity against human HepG2/C3A cells assessed as reduction in mitochondrial DNA copy numbers at 1 uM after 14 days relative to control2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID47622Cellular toxicity was measured in CEM cells after 8 days1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.
AID32242Percent cytotoxicity against ATH8 cells at a concentration of 0.2 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID30178Water solubility of the compound.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID104403Minimum compound concentration that reduced cell viability by 25% for HIV replication in MT-2 cells.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID584626Toxicity in human subcutaneous preadipocytes assessed as decrease of cell cultures at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID104246Effective concentration that increases formazan production in infected MT-2 cells1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.
AID71777Concentration that reduces Friend murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID106564Therapeutic index (TI) was determined by dividing the ID50 by the ED501992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and anti-HIV activity of 9-[c-4,t-5-bis(hydroxymethyl)cyclopent-2-en-r-1-yl]-9H-adenine.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1610153Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis2019European journal of medicinal chemistry, Dec-15, Volume: 184Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID238445Inhibitory constant against HIV-1 reverse transcriptase2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcriptase.
AID47138Effect on HIV-induced cytopathogenesis in CEM cells.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID584809Inhibition of electron transport protein complex 1/3 in human subcutaneous preadipocytes at 0.1 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1323001Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID235487Selectivity index is the ratio of IC50 to EC50 of F-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID583439Cytotoxicity against human HepG2 cells assessed as disrupted mitochondrial cristae at 10 uM after 15 days by electron microscopy relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID779525Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID52553Inhibitory activity based on the inhibition of [Ca2+] mobilization induced by human SDF-1alpha stimulation through CXCR4; N.T. means not tested2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1304400Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1422442Antiviral activity against Human adenovirus 2 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method2018Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID45026Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID235254Therapeutic index(TI) was measured as ratio of TD50 and MIC50 (Retrovirus)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Anti-HIV-I activity of linked lexitropsins.
AID28898Partition coefficient (logP)1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584813Inhibition of citrate synthase in human subcutaneous preadipocytes at 0.1 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID685332Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID104429Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID46246Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID334755Cytotoxicity against cat CRFK cells assessed as reduction in cell viability after 5 days by MTT assay1992Journal of natural products, Apr, Volume: 55, Issue:4
Fistularin 3 and 11-ketofistularin 3. Feline leukemia virus active bromotyrosine metabolites from the marine sponge Aplysina archeri.
AID1068975Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
AID1422437Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days by microscopic method2018Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
AID106922Concentration required to inhibit 50% of host cell replication in MT-2 cells used against HIV studies; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID1072798Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID88972Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID106590Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.
AID43694Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
AID1304402Cytotoxicity against mock-infected human CEM-SS cells2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID249725Effect of compound (10000 uM) on growth of CHO cells measured as population doublings from the beginning of the experiment as percent of controls after 20 hr of treatment (harvested at 42h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID1757989Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV-1 infected in human MT4 cells in presence of AZT2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID106919Anti-HIV activity against HIV-I IIIB strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID46440Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID665550Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID405351Toxicity against human HepG2/C3A cells assessed as increase in mitochondrial superoxide production at 1 to 5 uM by flow cytometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID717256Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID154932Effective conc. required to achieve 50% inhibition of HIV-1 IIIB multiplication in PBM (peripheral blood mononuclear) cells2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID1757990Antiviral activity against HIV-1 infected in human MT4 cells assessed as reduction in virus-indued cytopathogenicity incubated for 5 days in presence of ddA by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID200572The compound was tested for the cytotoxicity against Rauscher murine leukemia virus1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2',3'-dideoxycytidine and its 3'-fluoro derivative.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID105762Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID235196Therapeutic index (IC50/EC50) was determined1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID85723Concentration required to inhibit 50% of HSV-1 replication; not determined2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1449531Mitochondrial toxicity in human HepG2 cells assessed as lactic acid production at 10 uM measured on day 14 by spectrophotometric method relative to control2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID3002Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and anti-DNA viral activities in vitro of certain 2,4-disubstituted-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d d pyrimidine nucleosides.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID572767Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID584609Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA copy number per cell at 0.1 uM after 60 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID82981Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID1203825Mitochondrial toxicity in human HepG2 cells assessed as induction of lactic acid levels at 10 uM incubated for 14 days2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID105752Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration; Range is 40-601987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID584627Toxicity in human subcutaneous preadipocytes assessed as decrease of cell viability measured every 5 days at 0.1 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID584811Inhibition of electron transport protein complex 4 in human subcutaneous preadipocytes at 0.1 uM after 30 to 60 days by photometric analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID45025Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID141778Concentration inhibiting moloney murine leukemia retrovirus1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Anti-HIV-I activity of linked lexitropsins.
AID104272Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID235227Therapeutic index against SIV delta in CEM-SS cells was expressed as IC50/EC501998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID584633Toxicity in human subcutaneous preadipocytes assessed as decrease of C/EBPalpha expression at 3 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1203822Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
AID235482Selectivity index is the ratio of CC50 to EC50 values; Not determined2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID718372Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID104421Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID572995Mitochondrial toxicity in human HepG2 cells assessed as percent lactic acid production at 10 uM after 14 days by real-time PCR relative to beta-actin DNA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID44815Concentration of compound that inhibits incorporation of radiolabeled amino acids by 50 %1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).
AID583440Cytotoxicity against human HepG2 cells assessed as mitochondrial swelling at 10 uM after 15 days by electron microscopy relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID1757988Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID405350Toxicity in human H9c2 cells assessed as effect on cell viability at 5 uM after 6 days2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID361402Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay2002Journal of natural products, Nov, Volume: 65, Issue:11
New saponins from the starfish Certonardoa semiregularis.
AID614139Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 IIIB infected in human MT4 cells2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID233723Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 5(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID252593Percent of CHO cells with chromosomal aberrations were determined at 10000 uM compound after 20 hr of treatment (harvested at 30h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID779527Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID717254Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID252594Percent of CHO cells with chromosomal aberrations were determined at 10000 uM compound after 20 hr of treatment (harvested at 42h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID104776Concentration required to cause death of MT-4 cells was determined in vitro2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID105747Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.008 uM concentration.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID602908Toxicity against human MT4 cells by MTT assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
AID619629Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1322998Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID602910Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
AID1304404Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human CEM-SS cells to EC50 for antiviral activity against HIV-1 RF2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID619630Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID106918Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID1059727Cytotoxicity against human MT2 cells after 5 days by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.
AID614142Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID32066Required dose to reduce viability of normal uninfected ATH8 cells.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID47476Total viral index (TAI) is the area between the cytotoxicity and the antiviral activity curve for CEM cells.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235631Selectivity index determined for CC50 (test II) to EC50 x 10e3; Not tested2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID46437Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID217409Cytotoxic concentration to uninfected vero cells1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.
AID1757993Antiviral activity against HIV-1 infected in human CEM-TK(-) cells assessed as reduction in viral multiplication by measuring decrease in reverse transcriptase activity incubated for 6 days2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1614371Mitochondrial toxicity in human HepG2 cells 10 uM followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1757976Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID1304399Inhibition of HIV-1 BH10 recombinant reverse transcriptase expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rC)/oligo(dG) as template primer2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID89528Compound was tested in vitro against extracellular DNA hepatitis B virus of human liver cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methoxy(or azido)-5,6-dihydro-3'-fluoro-3'-deoxythymidine diastereomers. Potential prodrugs to 3'-fluoro-3'-deoxythymidine.
AID1304405Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human MT4 cells to EC50 for antiviral activity against HIV-1 3B2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID458192Activity at Drosophila melanogaster dNK by spectrophotometry2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis of fluorescent nucleoside analogs as probes for 2'-deoxyribonucleoside kinases.
AID199981Inhibition of HIV-1 reverse transcriptase; + = active1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
AID235628Selectivity index determined for CC50 (test I) to EC50 x 10e32001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
AID86719Effective concentration to inhibit hepatitis B virus cytopathicity in HepG2.2.15 cells was determined in vitro; No data2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID232746Selectivity index is calculated by dividing the TC25(CEM) by ID50(CEM)1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID46244Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID235223Therapeutic index against HIV-1 strain RF in CEM-SS cells was expressed as IC50/EC501998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
AID23457Partition coefficient (logP)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
AID583446Cytotoxicity against human HepG2 cells assessed as increase in extracellular lactate secretion at 10 uM after 15 days relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID588964Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID779526Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID584605Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA abundance at 0.1 uM after 30 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID685335Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID104399Total viral index (TAI) is the area between the cytotoxicity and the antiviral activity curve for MT-2 cell line.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID249724Effect of compound (10000 uM) on growth of CHO cells measured as population doublings from the beginning of the experiment as percent of controls after 20 hr of treatment (harvested at 30h of treatment)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5'-monophosphates as inhibitors of hepatitis C virus RNA replication.
AID718367Selectivity index, ratio of CC50 for HIV2 ROD infected in human MT4 cells to EC50 for HIV1 3B2012Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID105399AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
AID1757985Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID235458Selectivity index (SI) is determined as the ratio of CC50/EC502002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
AID584640Toxicity in human subcutaneous preadipocytes assessed as decrease of adiponectin expression at 0.1 uM after 30 days by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID584632Toxicity in human subcutaneous preadipocytes assessed as decrease of C/EBPalpha expression at 0.1 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID46371Anti-HIV activity against HIV-I RFII strain in CEM cell line1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
AID235206Therapeutic index for the compound was determined (IC50/EC50)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID584816Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial membrane potential at 0.1 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID32244Percent cytotoxicity against ATH8 cells at a concentration of 1 uM.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID154809Cytotoxic concentration which reduces the cell viability of HIV-1 IIIB infected PBM (peripheral blood mononuclear) cells2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.
AID1427834Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
AID1427837Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method
AID28713Partition coefficient (logP)1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID717258Cytotoxicity against human MT4 cells by MTT assay2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID45176Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
AID1304401Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1498117Antiviral activity against Adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID81256Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Potential prodrug derivatives of 2',3'-didehydro-2',3'-dideoxynucleosides. Preparations and antiviral activities.
AID584638Toxicity in human subcutaneous preadipocytes assessed as decrease of insulin-sensitizing adipokine expression at 0.1 uM after 30 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID1325060Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.
AID47300Compound was tested for its inhibitory activity against HIV replication in CEM cells.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Synthesis and anti-HIV activity of 4'-thio-2',3'-dideoxynucleosides.
AID572993Mitochondrial toxicity in human HepG2 cells assessed as percent mitochondrial DNA production at 10 uM after 14 days by real-time PCR relative to control2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID602909Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis of enantiomerically pure D- and L-bicyclo[3.1.0]hexenyl carbanucleosides and their antiviral evaluation.
AID572997Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 10 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID20871Partition coefficient (P) in 1-octanol and 0.1 M Na3PO4 at pH 71990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID249056Cytotoxicity against CEM cell lines of human2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Synthesis and antiviral activity of helioxanthin analogues.
AID56584Inhibitory affect against rabbit deoxycytidine kinase and represented as molt/4F kinase in two references.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID1322999Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID1757983Selectivity index, ratio of CC50 for human CEM-SS cells to EC50 for antiviral activity against HIV-1 infected in human CEM-SS cells in presence of ddA2021European journal of medicinal chemistry, Apr-15, Volume: 216An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs.
AID405356Toxicity against human H9c2 cells assessed as reduction in mitochondrial DNA copy numbers at 1 to 5 uM after 12 days relative to control2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
AID584631Toxicity in human subcutaneous preadipocytes assessed as decrease of PPARgamma expression at 3 uM after 18 days by RT-PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.
AID297680Antimycobacterial activity against Mycobacterium avium ATCC 25291 at 100 uM by microplate alamar blue assay2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235800Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID233725Compound was evaluated for the protective effect against HTLV-III/LAV (HIV) pathogenesis at a concentration of 50(uM)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID583455Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex IV activity at 10 uM after 15 days relative to control2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.
AID86851Concentration required to inhibit 50% of Hepatitis B virus replication2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,193)

TimeframeStudies, This Drug (%)All Drugs %
pre-199084 (7.04)18.7374
1990's775 (64.96)18.2507
2000's205 (17.18)29.6817
2010's112 (9.39)24.3611
2020's17 (1.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.38 (24.57)
Research Supply Index7.25 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index61.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials155 (12.40%)5.53%
Reviews118 (9.44%)6.00%
Case Studies33 (2.64%)4.05%
Observational0 (0.00%)0.25%
Other944 (75.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC [NCT00000679]Phase 2600 participants InterventionalCompleted
A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002 [NCT00000682]Phase 3120 participants InterventionalCompleted
A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC [NCT00000718]112 participants InterventionalCompleted
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 [NCT00000754]Phase 260 participants InterventionalCompleted
A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy [NCT00000651]Phase 3750 participants InterventionalCompleted
Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy. [NCT00000678]Phase 2320 participants InterventionalCompleted
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC [NCT00000753]Phase 130 participants InterventionalCompleted
A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy [NCT00000969]400 participants InterventionalCompleted
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 [NCT00000625]Phase 22,100 participants InterventionalCompleted
A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infecte [NCT00001048]Phase 290 participants InterventionalCompleted
Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303 [NCT00001087]Phase 2300 participants InterventionalCompleted
An Open-Label, Randomized, Dose-Finding, Multicenter Trial of Dideoxycytidine (ddC) Administered Concurrently With Zidovudine (AZT) in the Treatment of AIDS or Advanced ARC [NCT00000978]Phase 168 participants InterventionalCompleted
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy. [NCT00002256]0 participants InterventionalCompleted
Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma [NCT00000954]Phase 172 participants InterventionalCompleted
A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus [NCT00002436]Phase 3325 participants InterventionalCompleted
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Othe [NCT00002118]600 participants InterventionalCompleted
A Randomized, Multicenter, Double-Blind, Phase III, Parallel Study of Zidovudine (AZT) Alone Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus AZT Plus Saquinavir Mesylate (Ro 31-8959 ; HIV Proteinase Inhibitor) Versus AZT Plus ddC Plus Ro 31-8959 [NCT00002334]Phase 33,000 participants InterventionalCompleted
A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy [NCT00001029]Phase 2654 participants InterventionalCompleted
A Phase II Study to Evaluate Pharmacokinetics, Safety, Tolerance and Activity of Dideoxycytidine (ddC) Administered in Combination With Zidovudine (AZT) in Stable, AZT-Treated Pediatric Patients With HIV Infection [NCT00001032]Phase 2180 participants InterventionalCompleted
A Randomized, Comparative Trial of Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus Dideoxycytidine (ddC) in HIV-Infected Patients [NCT00001022]Phase 31,200 participants InterventionalCompleted
A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC. [NCT00000704]Phase 164 participants InterventionalCompleted
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) [NCT00000781]Phase 21,292 participants InterventionalCompleted
A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT [NCT00000653]Phase 2140 participants InterventionalCompleted
A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease [NCT00000719]96 participants InterventionalCompleted
Double-Blind, Randomized, Phase II Study of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Ro 31-8959 Plus AZT Plus ddC [NCT00001040]Phase 2300 participants InterventionalCompleted
A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A o [NCT00002386]Phase 455 participants InterventionalCompleted
A Phase I Pilot Study of the Safety and Efficacy of Interferon Alfa-2b (IFN Alfa-2b) in Combination With Nucleoside Analog Therapy in Patients With Combined Hepatitis C (HCV) and Advanced Human Immunodeficiency Virus (HIV) Infections [NCT00001035]Phase 110 participants InterventionalCompleted
The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease [NCT00002001]0 participants InterventionalCompleted
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy [NCT00002109]Phase 30 participants InterventionalCompleted
An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492 [NCT00002265]Phase 20 participants InterventionalCompleted
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection [NCT00002086]Phase 2256 participants InterventionalCompleted
RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience [NCT00000902]Phase 1217 participants InterventionalCompleted
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs [NCT00002162]Phase 2140 participants InterventionalCompleted
Pharmacokinetics and Bioavailability of Dideoxycytidine in Patients With Human Immunodeficiency Virus Infection [NCT00000997]12 participants InterventionalCompleted
A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase [NCT00002347]Phase 2225 participants InterventionalCompleted
Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease [NCT00002081]0 participants InterventionalCompleted
A Randomized, Double-Blind, Multicenter, Parallel Study of Ro 31-8959 (Saquinavir; HIV Proteinase Inhibitor) Alone, HIVID (Dideoxycytidine; Zalcitabine, ddC) Alone, and Both in Combination, as Treatment for Advanced HIV Infection (CD4 50-300 Cells/mm3) in [NCT00002333]Phase 2900 participants InterventionalCompleted
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection [NCT00002117]Phase 3528 participants InterventionalCompleted
Dideoxycytidine (Ro 24-2027). An Open-Label, Safety Study of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine (AZT) Therapy [NCT00002279]0 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]